August 10, 2023 5:03pm

Yet, sentiment seems to be slipping as exits appear post earnings. My question, are we facing a prisoner’s dilemma- a situation wherein algorithms acting with electronic trading interest do not achieve the optimal outcome for the investor group

Pre-Open Indications: 2 Hit and 3 Miss

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

Never leave an investor uninformed!

 

If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-military officer and x-FBI, an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to our knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +52.79 or +0.15%, the S&P closed UP +1.12 or +0.03%% while the Nasdaq closed UP +15.97 points (+0.12%)

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Thursday’s market session and the cell and gene therapy sector ended slightly higher.

Economic Data Docket: July consumer prices gained 3.2% on an annual basis, less than the 3.3% consensus from economists. On a month-to-month basis, inflation increased 0.2%, in-line with estimates. The report also said real average weekly earnings were unchanged last month in another positive sign.

 

Thursday (8/10) … RegMed Investors’ (RMi) Opening Bell: “Expectation of +0.2% met in consumer price index in July” … https://www.regmedinvestors.com/articles/13072

 

Pre-Open Indications: 2 Hits < Caribou Biosciences (CRBU +$0.29), Mesoblast (MESO +$0.02)> and 3 Miss < Beam Therapeutics (BEAM -$0.71), bluebird bio (BLUE -$0.16), CRISPR Therapeutics (CRSP -$0.88>   

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences …

  • Thursday’s advance/decline line opened positive at 25 up/ 8 down and 2 flats, stayed positive with 22 up/ 12 down and 1 flat at the mid-day, ending with a negative close of 16 incliners, 18 decliners and 1 flat

 

Ebb and flow:

  • Q3: August – 2 positives and 6 negative closes

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday the IBB was up +0.33% and the XBI was up +0.86%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was down -0.11 point or -0.69% at 15.85

 

Closing Down (10 of 18):

  • Alnylam Pharmaceuticals (ALNY -$1.33)
  • CRISPR Therapeutics (CRSP -$0.88)
  • Beam Therapeutics (BEAM -$0.71 after Wednesday’s -$0.14 after Monday’s -$1.58),
  • BioLife Solutions (BLFS -$0.69 after Wednesday’s -$5,28 after Tuesday's -$0.25),
  • Prime Medicine (PRME -$0.59),
  • Intellia Therapeutics (NTLA -$0.47),
  • AxoGen (AXGN -$0.43),
  • Ultragenyx Pharmaceuticals (RARE -$0.31),
  • Vericel (VCEL -$0.29 after Wednesday’s -$0.64 after Tuesday's +$0.90),
  • Editas Medicine (EDIT -$0.18),

Flat (1):

  • Harvard Apparatus RM (HR)

Closing Up (10 of 16):

  • Blueprint Medicine (BPMC +$1.40),
  • Verve Therapeutics (VERV +$0.47),
  • Sage Therapeutics (SAGE +$0.37),
  • Caribou Bioscience (CRBU +$0.29 after Wednesday’s -$0.04),
  • Precigen (PGEN +$0.28),
  • MiMedx (MDXG -$0.16 after Wednesday’s -$0.12),
  • Voyager Therapeutics (VYGR +$0.08 after Wednesday +$0.16),
  • Solid Biosciences (SLDB -$0.08 after Wednesday’s -$0.11),
  • Cellectis SA (CLLS +$0.05),
  • Generation Bio (GBIO -$0.05 after Wednesday’s -$0.19),

 

Q3/23 – August

  • Thursday closed negative with 16 incliners, 18 decliners and 1 flat

 

The BOTTOM LINE: I try to keep it simple … and short!

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

The sector froze after cooling since 8/1 … as Q2/23 earnings LPS (loss-per-share) get released

“U.S. indexes closed lower, on Wednesday, the day after a report showed Americans borrowed more than ever on their credit cards in the last quarter, and a day ahead of U.S. Consumer Price Index (CPI) inflation data that could influence Federal Reserve interest rate decisions.” <Reuters>

August tends to frighten many stock market investors and historians.

·         The stock market is riding high after a strong performance in July, but August could be a difficult month for investors.

·         Data compiled by the Stock Trader’s Almanac shows the S&P 500 averages just a 0.1% gain in August. That makes it the third-worst month on average for the benchmark index. The Dow, meanwhile, averages a loss of 0.04% in August. <CNBC>

 

Cell and gene therapy sector performance continues to suggest the results of earning season…

Q2/23 net losses earnings, cash positions and runway outcomes. LPS (loss-per-share) releases will present challenges to share pricing with outcomes included … https://www.regmedinvestors.com/articles/13058

 

Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

 

The top three (3) performing in the session:

Thursday: Blueprint Medicine (BPMC), Verve therapeutics (VERV) and Sage Therapeutics (SAGE)

Wednesday: Ultragenyx (RARE), Alnylam Pharmaceuticals (ALNY) – again, and Blueprint medicine (BLMC)

Tuesday: CRISPR Therapeutics (CRSP), Sage Therapeutics (SAGE) and Alnylam Pharmaceuticals (ALNY)

Monday: Solid Biosciences (SLDB), Precigen (PGEN) and Bellicum Pharmaceuticals (BLCM)

 

While The worst three (3) in the session:

Thursday: Alnylam Pharmaceuticals (ALNY), Beam therapeutics (BEAM) and CRISPR Therapeutics (CRSP) - again

Wednesday: BioLife Solutions (BLFS) – again, CRISPR Therapeutics (CRSP), and Vericel (VCEL)

Tuesday: AxoGen (AXGN), Ultragenyx (RARE) and BioLife Solutions (BLFS)

Monday: Sage Therapeutics (SAGE) and Bellicum Pharmaceuticals (BLCM)

 

I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.

 

The NO spin zone! U.S. public shareholders deserve accountability …

 

Harvard Apparatus Regenerative Technology (HRGN)  formerly Biostage (OTCQB: BSTG) … as of 7/20/23 -- so many issues!

·         Question: is HRGN just another Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold?

·         Accumulated deficit:  $85,901 M

·         Will HRGN ESCAPE the scandals when its “former” corporate name was used by a former chairman and CEO Green initiating scandal plagued utilization of an Italian surgeon and the $5 M it took to settle out the executive responsibility as it was SHIFTED to the company shareholders and Harvard Bio (HBIO)???

·         Can this management team be TRUSTED by ANY shareholder other then major holders’ Chinese off-shore investors.

·         HRGN schedules earnings LPS (loss-per-share) conference call on 8/14

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.